Again, CYP does not need 3D so I don't get why you are asking about CYP doing something that they're not doing.
Re your question, we are not the FDA, we don't decide to what extent variation in manufacture to that approved process is acceptable. So will the FDA make MSB do additional trials if they alter their manufacturing process by introducing 3D? how is anybody here supposed to know what the FDA will decide? is it a risk that the FDA will require some additional trials or tests? Yes. But only the FDA will know what they will require.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $35.02M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $13.23K | 85.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7889 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 243 | 1 |
View Market Depth
| Last trade - 13.39pm 07/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |